奥曲肽辅助治疗肝硬化顽固性腹水的临床疗效分析  

Clinical Efficacy of Octreotide in the Treatment of Refractory Ascites Due to Cirrhosis

作　　者：郭龙[1] 冯岳[2] GUO Long;FENG Yue(The Second Affiliated Hospital of Baotou Medical College/Institute of Digestive Diseases of Inner Mongolia Autonomous Region,Baotou,Inner Mongolia 014030;ICU,the Second Affiliated Hospital of Baotou Medical College,Baotou,Inner Mongolia 014030)

机构地区：[1]包头医学院第二附属医院/内蒙古自治区消化病研究所,内蒙古包头014030 [2]包头医学院第二附属医院ICU,内蒙古包头014030

出　　处：《智慧健康》2019年第34期57-59,共3页Smart Healthcare

摘　　要：目的分析探讨奥曲肽辅助治疗肝硬化顽固性腹水的临床疗效。方法选取我院于2016年6月至2019年6月收治的76例肝硬化顽固性腹水患者作为研究对象。按照随机分配的方式分为对照组(38例)和观察组(38例);对照组患者实施常规的治疗,观察组患者实施奥曲肽辅助治疗,治疗过程中对两组缓解的治疗效果进行有效的观察。结果两组患者在接受治疗后均取得了一定的效果,但观察组患者的效果明显优于对照组,差异均有统计学意义(P<0.05)。结论利用奥曲肽辅助治疗肝硬化顽固性腹水的临床效果显著,能够改善患者的临床症状。提高有效治愈率以及治疗满意度,降低不良反应的发生率,有较高的应用价值,值得推广。Objective To analyze the clinical efficacy of octreotide in the treatment of refractory ascites due to cirrhosis.Methods Sixty-six patients with refractory ascites from cirrhosis who were admitted to our hospital from June 2016 to June 2019 were enrolled.According to the random distribution method,they were divided into the control group(38 cases)and the observation group(38 cases).The control group patients received routine treatment,and the observation group patients were treated with octreotide adjuvant therapy.The treatment effect of the two groups was effective during the treatment observation.Results Both groups achieved certain effects after receiving treatment,but the effect of the observation group was significantly better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Octreotide can improve the clinical symptoms of patients with refractory ascites due to cirrhosis.To improve the effective cure rate and treatment satisfaction,reduce the incidence of adverse reactions,has higher application value,is worth promoting.

关 键 词：奥曲肽 肝硬化 顽固性腹水 临床疗效 

分 类 号：R575.2[医药卫生—消化系统]